EXECUTIVE SUMMARY: FOUNDATION FOR AI-DRIVEN PRECISION MEDICINE

Tempus AI operates a unique, strategically integrated, dual business model designed to serve as the core data infrastructure for personalized medicine. The operational framework leverages its high-volume diagnostic business (Genomics segment) as a compensated, quality-controlled engine for data acquisition. This proprietary, multimodal Real-World Data (RWD) is then monetized through the high-margin Data and Services segment via AI-driven software, data licensing, and research partnerships.¹

The company demonstrated significant momentum and strategic execution in Fiscal Year (FY) 2024, achieving total revenue of $693.4 million, representing 30.4% year-over-year (YoY) growth. Critically, the Data and Services segment is demonstrating increasing financial leverage, outpacing the core business with 43.2% YoY growth, resulting in accelerated gross profit expansion.² Management forecasts a crucial strategic inflection point in 2025, projecting annual revenue of $1.24 billion and the achievement of positive Adjusted EBITDA, a significant $110 million improvement over 2024 performance.²

Strategic execution in 2025 emphasizes scaling and differentiation. Recent strategic moves include key acquisitions—Ambry Genetics to increase genomic data depth and scale ⁴, and Paige to expand the multimodal data moat into digital pathology.⁵ The value of Tempus’s data assets has been externally validated through high-value, sticky partnerships, notably the multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal oncology foundation model, secured by $200 million in data licensing and development fees.⁶ Simultaneously, Tempus is institutionalizing its AI tools in clinical workflows via major Electronic Health Record (EHR) integrations of its ‘David’ generative AI co-pilot, exemplified by its partnership with Northwestern Medicine.⁷ This comprehensive strategy is aimed at establishing market leadership by embedding Tempus’s platform across the R&D and clinical care ecosystems.

I. COMPANY OVERVIEW AND CORPORATE PROFILE

A. Genesis and Founding Vision

Tempus AI was founded and is led by CEO Eric Lefkofsky.⁸ Lefkofsky is a highly successful serial entrepreneur with a long track record of building and scaling massive technology platforms, including co-founding Groupon, Echo Global Logistics, and Mediaocean.⁹ This foundational experience in large-scale technology infrastructure provides Tempus with an architectural blueprint built for complex data management and rapid iteration, distinguishing the company from traditional life sciences or clinical diagnostic organizations. The core challenge for Tempus—managing vast, heterogeneous healthcare data across diverse health systems—is directly addressed by the platform expertise brought by its leadership.

Lefkofsky’s motivation for founding Tempus was rooted in a personal desire to solve complex problems in healthcare through the practical application of artificial intelligence, underscoring a commitment that drives rapid scaling and resource dedication.⁸ Tempus’s platform originated with a singular focus on oncology, recognizing the urgent need for personalized cancer diagnostics. However, the technology was designed to be fundamentally generalizable, allowing for rapid expansion into diverse clinical and molecular data sets across neuropsychiatry, cardiology, infectious disease (notably through COVID), and radiology.⁴

B. Defining Mission: Personalizing Diagnosis and Therapy via Data and AI

The core objective of Tempus’s mission is to help ensure patients receive “the right drug at the right time,” enabling them to live longer and healthier lives.¹⁰ This mission is implemented through a critical technological strategy: constructing a platform capable of ingesting real-time healthcare data and combining molecular data (from sequencing) with comprehensive clinical data extracted directly from providers’ Electronic Medical Record (EMR) systems.⁴ This rigorous integration process allows for the personalization of diagnostics and the generation of contextually relevant clinical test reports for individual patients.⁴ The platform’s ability to successfully replicate this data integration model beyond oncology into other disease areas validates the scalability and architectural flexibility of the underlying technology stack.

C. Core Operational Philosophy: The Patient-Centric, Data-Driven Culture

The operational philosophy, encapsulated in the “Tempus Culture Code,” establishes a data-driven environment characterized by transparency, integrity, accuracy, and a palpable “sense of purpose and urgency”.¹¹ The company explicitly frames its endeavor as a “battle” against life-threatening diseases, declaring its commitment to “win on behalf of the patients we serve – period”.¹¹

This cultural mandate for urgency directly supports Tempus’s competitive strategy of rapid data aggregation and market diversification. In the AI and Real-World Data (RWD) sector, the first entity to achieve critical mass of high-quality, multimodal data establishes the de facto industry standard. This standard attracts the highest-value biopharma and health system partnerships, thereby accelerating the accumulation of proprietary data and forging a powerful network effect that competitors struggle to match. The commitment to recruit, reward, and retain the best talent is therefore not merely a human resources policy, but an essential component of the strategy required to maintain this aggressive scaling tempo necessary for platform dominance.¹¹

II. CORE BUSINESS SEGMENTS AND THE MULTIMODAL PLATFORM

Tempus’s business model is fundamentally structured around two interdependent segments: the Genomics segment, which produces the essential data inputs, and the Data and Services segment, which monetizes the resulting insights and platform access.

A. The Tempus Technology Ecosystem

The Tempus platform serves as the central architecture facilitating the integration of diverse, longitudinal molecular and clinical data.⁴ This integrated data foundation supports a suite of proprietary AI-enabled products, designed to provide layered insights and integrate seamlessly into healthcare workflows.⁷

The modular AI product suite includes:

• ONE (e.g., David): An AI-enabled assistant, designed to support clinicians and researchers by handling natural language queries, generating pre-appointment summaries, intelligent note-taking, and documentation.⁷
• NEXT: A care management tool designed to continuously monitor patient data, identifying at-risk patients and alerting their care teams of any guideline-based follow-up or disease progression requirements.⁷
• LENS: The data visualization and analysis tool used by partners to find, access, and analyze multimodal RWD gathered by the platform.⁷
• ALGOS: Proprietary algorithmic models connected to Tempus’s assays, providing additional, context-specific insights layered on top of raw sequencing and clinical data.⁷

B. Segment I: Genomics and Diagnostic Lab Services (The Data Engine)

The Genomics segment functions as the operational “backbone” of Tempus’s strategy, responsible for running diagnostic tests.¹ Operating CAP-accredited, CLIA-certified labs, this segment offers comprehensive contract and traditional clinical sequencing options.¹⁴ Key offerings include diverse assays covering oncology and hereditary genetics, such as targeted panels (Tempus xT, 648 genes), whole transcriptome sequencing (xR), whole exome assays (xE), and liquid biopsy profiling (xF/xF+).⁷ This segment also provides sophisticated specimen analysis for immunotherapy platforms, assessing metrics like Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) status, and Neoantigen Prediction.¹⁴

The Genomics segment serves a vital dual purpose:

1. Revenue Generation: Generating direct revenue via test reimbursement from insurers or pharma sponsors.¹
2. Proprietary Data Acquisition: More strategically, it acts as a high-throughput, quality-controlled engine for generating the proprietary, structured molecular data that feeds the AI platform.¹

The necessity of controlling the diagnostic process to generate the data for the Data and Services platform inherently ensures high data quality and structure. Unlike competitors who often rely on licensing disparate data from external sources, Tempus controls the entire process—from sample handling and sequencing protocol (xT, xR) to EMR integration. This control minimizes noise and maximizes the utility of the resulting multimodal data, which is essential for training superior, healthcare-specific AI models that consistently outperform general-purpose models on clinical tasks.⁴

C. Segment II: AI, Data Licensing, and Software Services (The Value Multiplier)

The Data and Services segment monetizes the vast, proprietary dataset generated by the Genomics segment through software subscriptions, data licensing (branded as Insights), and clinical research organization (CRO) partnerships.¹ This segment represents the highest-margin revenue stream and is the primary driver of the company’s operating leverage and profitability expansion.

Generative AI in Clinical Workflow

A critical component of this segment is the strategic deployment of Generative AI tools directly into clinical practice. The ‘David’ Clinical Co-Pilot (part of the ONE product) is designed specifically to assist clinicians, aiming to ease administrative burdens and enhance clinical decision-making.¹² Its functions include note-taking and documentation, pre-appointment preparation, and providing multimodal patient record support.¹²

The integration of David within major hospital systems, such as Northwestern Medicine’s EHR platform ⁷, represents more than a transactional software sale; it constitutes a profound institutional integration that establishes Tempus’s presence across the entire care continuum. By solving immediate clinician pain points (e.g., reducing documentation time), Tempus earns physician trust and secures continuous access to the freshest clinical data, thereby strengthening its RWD platform (LENS and NEXT) and improving the conversion rate for diagnostic orders. This approach creates a powerful network effect and significantly increases customer switching costs.

AI-Powered Regulated Diagnostics

Tempus is actively translating its research and development capabilities into regulated software as a Medical Device (SaMD) to address large, high-volume markets beyond oncology. This expansion strategy is validated by the successful attainment of multiple FDA 510(k) clearances. For instance, the company received 510(k) clearance for Tempus ECG-Low EF software, which analyzes standard ECG data to provide a binary output identifying patients who may have a low left ventricular ejection fraction.⁷ Similarly, the Tempus ECG-AF device uses AI algorithms to help identify patients at increased risk of atrial fibrillation/flutter (AF).¹³

These clearances demonstrate institutional maturity in navigating regulatory hurdles and validate the platform’s architectural flexibility. The successful application of the integrated data model (molecular + clinical data) into new disease areas like cardiology and neurology confirms that Tempus is fundamentally a technology platform company capable of rapid market diversification, dramatically expanding its Total Addressable Market (TAM) beyond specialized cancer services.⁴

III. REVENUE STRUCTURE AND FINANCIAL PERFORMANCE ANALYSIS

Tempus’s financial structure reflects its hybrid business model, with the Genomics segment providing the foundational revenue and the Data and Services segment providing the critical acceleration vector towards profitability.

A. Segmental Revenue Breakdown and Growth Vectors

The accelerating growth of the Data and Services segment is the defining financial narrative of the company’s transition toward operational maturity.

Table Title: Tempus AI Financial Summary: FY 2024 Segment Performance (USD Millions)

Metric	Total Revenue	Genomics Revenue	Data and Services Revenue	YoY Growth Rate (Total)
FY 2024 Results	$693.4M	$451.7M	$241.6M	30.4%
Q4 2024 Results	$200.7M	$120.4M	$80.2M	35.8%
FY 2024 Growth Rate	N/A	24.4%	43.2%	N/A
Q4 2024 Growth Rate	N/A	30.6%	44.6%	N/A
Data Source: 2

B. Financial Results for Fiscal Year 2024

Annual revenue in 2024 reached $693.4 million, representing a 30.4% year-over-year increase.² Revenue growth accelerated in the fourth quarter (Q4) of 2024 to 35.8% YoY, reaching $200.7 million.³

The data confirms the superior growth of the monetization segment:

• Genomics Revenue: Generated $451.7 million in 2024, reflecting a solid 24.4% YoY growth, supported by a 23.8% increase in unit volume.²
• Data and Services Revenue: Generated $241.6 million, demonstrating a faster growth rate of 43.2% YoY.²

C. Gross Margin Dynamics and Profitability Trajectory

The strong performance of the Data and Services segment is translating directly into favorable margin dynamics. Annual gross profit increased to $381.1 million in 2024, representing 33.2% growth year-over-year. In Q4 2024, gross profit growth accelerated significantly to 49.7%, substantially outpacing the 35.8% revenue growth, a change specifically led by the Data and Services segment.² This pattern is highly indicative of strong margin expansion driven by the increasing proportional contribution of high-margin software and data licensing sales.

Furthermore, indicators of customer stickiness and future revenue visibility are robust. Tempus ended 2024 with $940 million in Total Remaining Contract Value (TRCV) and an improved Net Revenue Retention (NRR) rate of 140%.² These metrics are crucial financial validation points, demonstrating that existing pharma and health system customers are expanding their engagements significantly year-over-year. This growth confirms successful cross-selling and deep integration of the platform’s AI and data products (LENS, David), reflecting the high cost of switching platforms once Tempus’s RWD becomes embedded in the client’s R&D or clinical decision framework.

Despite the strong growth and margin accretion, the company reported a net loss of ($705.8 million) in 2024, although Adjusted EBITDA showed substantial improvement, reaching ($104.7 million).²

D. 2025 Financial Guidance and Path to Adjusted EBITDA Positive

Management has provided forward guidance signaling a critical strategic inflection point for 2025. Tempus increased its revenue guidance to $1.24 billion for the full year 2025.²

More significantly, the company expects to achieve positive Adjusted EBITDA of approximately $5 million for the full year 2025, representing an improvement of approximately $110 million over 2024.² Early results in 2025 confirmed this trajectory, with Q3 2025 results reporting positive Adjusted EBITDA of $1.5 million, a $23.3 million improvement over the prior year quarter.⁵ This projected achievement, sometimes referred to as the “Inversion Thesis,” hinges on the operating leverage derived from the Data and Services segment, which increases its proportional mix of total sales. The Insights (data licensing) sub-segment was noted as a key driver of this profitability, achieving 37.6% YoY growth.⁵ The aggressive revenue guidance for 2025 must also be viewed in the context of strategic M&A, specifically the integration of Ambry Genetics, closed in February 2025, which provides a substantial boost to the Genomics segment’s revenue and clinical volume, supporting the overall target.³

IV. GROWTH STRATEGY AND STRATEGIC EXPANSION

Tempus’s growth strategy is multifaceted, focusing on expanding its therapeutic footprint, executing synergistic mergers and acquisitions, and solidifying high-value data monetization through strategic partnerships.

A. Therapeutic and Disease Area Diversification

The company continues to execute its systemic expansion strategy by applying its core AI platform and data integration model to new, high-volume disease categories.¹⁰ Beyond the original oncology focus, validated success in integrating molecular and clinical data has enabled movement into cardiology, neuropsychiatry, and radiology.⁴

This therapeutic expansion is underpinned by the strategic pursuit of regulatory milestones for its AI tools. The attainment of FDA 510(k) clearances for AI algorithms, such as Tempus ECG-AF (identifying risk for atrial fibrillation) ¹³ and Tempus ECG-Low EF (identifying risk for low ejection fraction) ¹⁶, demonstrates a capability to enter new clinical markets quickly and scalably using FDA-validated Software as a Medical Device (SaMD). Leveraging standardized, high-volume data inputs (like ECGs) allows Tempus to achieve rapid commercialization in new clinical areas, validating the platform’s versatility.

B. Strategic Mergers and Acquisitions (M&A)

Tempus employs a calculated M&A strategy focused on acquiring essential data inputs and expertise required for its foundation models.

The acquisition of Ambry Genetics (closed February 2025) was strategic for scaling the platform’s capacity and data depth.³ Ambry significantly enhanced the genomic dataset by adding approximately 3 million genomic sequences from hereditary cancer testing.⁴ This acquisition directly increased the volume and scale necessary to support the 2025 revenue guidance and accelerate data accumulation.

The subsequent acquisition of Paige (a specialist in digital pathology AI, acquired Q3 2025) was critical for expanding the definition of the multimodal data moat.⁵ This acquisition ensures Tempus can integrate high-resolution imaging data alongside existing genomic and clinical data streams, positioning it at the forefront of AI model development that requires truly multimodal inputs.

These acquisitions demonstrate a strategic clarity: Tempus is systematically integrating the previously fragmented components of patient data (genomics, clinical EMR, pathology images) into one closed loop. This synergy allows Tempus to acquire the necessary inputs (volume from Ambry, imaging modality from Paige) to train the highly valuable output (the multimodal foundation model) required by large pharmaceutical partners.

C. High-Value Data Monetization and Partnership Model

The monetization strategy centers on securing high-value, multi-year commitments from major biopharma partners who rely on Tempus’s RWD and AI platform for drug development.

Multimodal Foundation Model Development

Tempus solidified a multi-year, strategic collaboration with AstraZeneca and Pathos AI aimed at leveraging Tempus’s vast data repository to build the largest multimodal foundation model in oncology.⁶ Tempus’s de-identified oncology data will be utilized to construct this model, which will then be shared among the three parties.¹⁸ The agreement confirms the extraordinary value of Tempus’s structured data set, securing $200 million in data licensing and model development fees for the company.⁶ This partnership structurally positions Tempus as an essential data infrastructure provider for global pharmaceutical research and development, confirming high pricing power for its proprietary data assets.

CRO Services and Institutional Validation

The platform’s capability to manage complex research was further validated by its selection by the Advanced Research Projects Agency for Health (ARPA-H) to provide testing and CRO services in support of the agency’s ADAPT (Advanced Analysis for Precision Cancer Therapy) program.⁵ This role confirms Tempus’s standing as a reliable, high-volume research partner for complex government and institutional initiatives.

Table Title: Major Strategic Partnerships and Expansion Initiatives

Partner/Initiative	Focus Area	Strategic Impact	Financial/Regulatory Data
AstraZeneca & Pathos AI	Multimodal Oncology Foundation Model	Establishes Tempus as essential data infrastructure for global R&D; secures multi-year, high-value commitment.	$200M in licensing/development fees 6
Ambry Genetics Acquisition (2025)	Hereditary Cancer Testing & Scale	Substantial increase in data volume (3M genomic sequences); supports scale needed for 2025 guidance.	Supports 2025 $1.24B revenue guidance 2
Paige Acquisition (Q3 2025)	Digital Pathology / Imaging AI	Expands multimodal data moat into critical imaging domain; necessary for next-gen foundation models.	Establishes leading footprint in digital pathology 5
Northwestern Medicine	EHR Integration of “David” Co-Pilot	Institutional validation and blueprint for scalable commercialization of Generative AI tools in clinical settings.	Eases administrative burden; enhances clinical decision-making 7
FDA 510(k) Clearances (Cardiology)	High-Volume AI Diagnostics (ECG-Low EF, ECG-AF)	Market diversification into cardiology; regulatory validation of SaMD approach.	Second FDA-cleared ECG-AI device 16

V. MARKET OPPORTUNITIES, DRIVERS, AND COMPETITIVE ADVANTAGE

A. Macro Market Drivers: Demand for Personalized Medicine and RWD Utilization

Tempus AI is exceptionally well-positioned to capitalize on significant macro market drivers. There is an increasing global demand for personalized medicine, requiring individualized treatment plans based on data-driven insights.¹⁹

Furthermore, the biopharmaceutical industry faces structural challenges, including lengthy, expensive drug development cycles and high failure rates in clinical trials, particularly in Phase II where improper patient selection is a common cause of failure.²⁰ On average, developing an anti-cancer drug takes about seven years from investigational new drug status to approval.²⁰ Real-World Data and AI platforms are becoming vital infrastructure to mitigate these risks. Tempus’s platform reduces risk and compresses R&D timelines by improving patient selection, optimizing trial design, and streamlining enrollment (approximately 25% of clinical trials fail due to insufficient patient enrollment).²⁰ By targeting these financial bottlenecks, Tempus aligns its high-margin data services directly with its partners’ highest financial stakes, ensuring pricing power and maximum value extraction from its platform.

B. The Tempus Competitive Moat

The company’s core competitive advantage stems from its integrated, dual business model, which represents a unique architectural differentiator.¹⁵

Architectural Integration and Data Superiority

Tempus pioneered the combination of a high-volume diagnostics lab (generating quality data) with a sophisticated software/data licensing business (monetizing the data).¹ This vertical integration allows Tempus to control the entire data lifecycle, layering comprehensive, multimodal patient information (molecular, clinical, and now imaging via Paige) onto test results, yielding richer, actionable insights that specialized competitors cannot match.¹⁵ This controlled data environment is why models trained exclusively on high-quality, multimodal healthcare data consistently outperform general AI models on clinical tasks.⁴

Network Effects and Scaling

The platform benefits from powerful data network effects. Every new health system partnership, clinical EHR integration (like the ‘David’ co-pilot deployment) ¹², and diagnostic volume increase contributes proprietary, structured RWD. This perpetually growing data pool makes the resulting AI models (ALGOS) and RWD products (LENS, Insights) increasingly accurate and valuable for all partners—a cycle that accelerates data aggregation and compounds the competitive advantage.

C. Competitive Landscape and Moat Sustainability

Tempus contrasts sharply with rivals that employ siloed approaches.¹⁵ For example, established entities like Foundation Medicine (owned by Roche) focus primarily on genomic testing, while Flatiron Health (also owned by Roche) specializes in oncology EHR data. Tempus’s integrated platform provides the holistic, multimodal data that surpasses the offerings of these single-domain specialists, allowing it to serve both the diagnostics market and the R&D/data licensing market simultaneously.¹⁵

While the company possesses these architectural advantages, a competitive assessment suggests the competitive moat is currently “discernible but modest,” registering a score of 4/10.²¹ This assessment implies that Tempus must aggressively pursue its scaling strategy throughout 2025—driven by M&A, high-value data partnerships, and clinical workflow integration—to transition from a modest advantage to a durable, wide competitive moat that is difficult for capitalized rivals to replicate. The success in securing multiple FDA 510(k) clearances also serves to increase regulatory barriers for AI competitors, setting the standard for data quality and regulated clinical deployment.

VI. DISCLAIMER

This report has been prepared for informational and analytical purposes only. The information presented herein is based on publicly available data, including company financial reports and regulatory filings. This document does not constitute, and should not be construed as, investment advice, an offer to sell, or a solicitation of an offer to buy any securities or related financial instruments. Readers should conduct their own comprehensive due diligence and consult with qualified financial professionals before making any investment decisions.

Works cited

1. Tempus AI (TEM): At the Crossroads of Diagnostics and Data, accessed November 30, 2025, https://mlq.ai/research/tempus-ai-tem-deep-dive/
2. Tempus Reports Fourth Quarter and Full Year 2024 Results, accessed November 30, 2025, https://www.tempus.com/news/tempus-reports-fourth-quarter-and-full-year-2024-results/
3. Tempus Reports Fourth Quarter and Full Year 2024 Results, accessed November 30, 2025, https://investors.tempus.com/news-releases/news-release-details/tempus-reports-fourth-quarter-and-full-year-2024-results/
4. Advancing the frontier of AI in healthcare – Tempus, accessed November 30, 2025, https://www.tempus.com/resources/content/blog/advancing-the-frontier-of-ai-in-healthcare/
5. Tempus Reports Third Quarter 2025 Results, accessed November 30, 2025, https://www.tempus.com/news/tempus-reports-third-quarter-2025-results/
6. Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology, accessed November 30, 2025, https://investors.tempus.com/news-releases/news-release-details/tempus-signs-expanded-strategic-agreements-astrazeneca-and
7. Tempus | AI-enabled precision medicine, accessed November 30, 2025, https://www.tempus.com/
8. Eric Lefkofsky | Entrepreneur & Philanthropist – Eric Lefkofsky is the founder and CEO of Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare., accessed November 30, 2025, https://lefkofsky.com/
9. Eric Lefkofsky – Wikipedia, accessed November 30, 2025, https://en.wikipedia.org/wiki/Eric_Lefkofsky
10. Our History – Tempus, accessed November 30, 2025, https://www.tempus.com/about-us/our-history/
11. Working at Tempus | Culture, accessed November 30, 2025, https://www.tempus.com/about-us/culture/
12. Northwestern Medicine 1st to integrate Tempus AI co-pilot into EHR – Becker’s Hospital Review | Healthcare News & Analysis, accessed November 30, 2025, https://www.beckershospitalreview.com/healthcare-information-technology/ehrs/northwestern-medicine-1st-to-integrate-tempus-ai-co-pilot-into-ehr/
13. Cardiology Care Gap Solutions – Tempus, accessed November 30, 2025, https://www.tempus.com/life-sciences/cardiology-care-gap-solutions/
14. Academic & Clinical Research Services | Tempus, accessed November 30, 2025, https://www.tempus.com/research/
15. Tempus AI ($TEM): A Deep Dive – BBAE Pro, accessed November 30, 2025, https://www.bbae.com/blog/tempus-ai-tem-a-deep-dive/
16. Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software, accessed November 30, 2025, https://www.tempus.com/news/pr/tempus-receives-u-s-fda-510k-clearance-for-tempus-ecg-low-ef-software/
17. Tempus Reports Third Quarter 2025 Results, accessed November 30, 2025, https://investors.tempus.com/news-releases/news-release-details/tempus-reports-third-quarter-2025-results/
18. Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology, accessed November 30, 2025, https://www.tempus.com/news/tempus-signs-expanded-strategic-agreements-with-astrazeneca-and-pathos-to-develop-the-largest-multimodal-foundation-model-in-oncology/
19. TEM Stock Analysis: What’s the Target Price for Tempus AI stock? – Markets.com, accessed November 30, 2025, https://www.markets.com/analysis/tem-stock-analysis-what-s-the-target-price-for-tempus-ai-stock
20. Oncology innovation: How emerging biotechs lead through RWD & AI – Tempus, accessed November 30, 2025, https://www.tempus.com/resources/content/articles/oncology-innovation-how-emerging-biotechs-lead-through-rwd-and-ai/
21. TEM (Tempus AI) Moat Score – GuruFocus, accessed November 30, 2025, https://www.gurufocus.com/term/moat-score/TEM